Recorded Webinar from July 28, 2020

 

Microfluidic, Nanoliter-scale Immunoassays for Rapid SARS-CoV-2 Antibody Analysis in Serology Testing, and Vaccine and Biotherapeutics Development

 

The unprecedented vaccine and therapeutic development efforts in response to the COVID-19 pandemic has created an urgent need for rapid, accurate, and sensitive assays to measure antibody responses to the SARS-CoV-2 virus. To meet this need, a microfluidic, nanoliter-scale immunoassay for qualitative detection of total antibodies generated against the spike protein (RBD) of SARS-CoV-2 in human serum samples has been developed using Gyrolab immunoassay platform. The assay shows specificity towards SARS-CoV-2 antibodies in serum samples, and a broad range of approximately 40 to 200,000 ng/mL. With an assay completion time of one hour for 112 data points, high-throughput analysis is possible for serology tests and for immunoassays during vaccine or antibody therapeutic development.


Robert-Durham-Thumbnail
Rob Durham, Ph.D.

Director of Service and Scientific Support
Gyros Protein Technologies

 

 

 

If you have problems to view the webinar please contact maritha.lundin@gyrosproteintech.com

 

Please register to access the webinar